DIANA PHAM: Open Payments
NPI 1346627312 · WEBSTER, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,946 in 91 payments from 22 companies in 2025. Trend: 2023 $1,965 · 2024 $1,364 · 2025 $1,946
Food & beverage: $1,946
| Company | Payments | Amount |
|---|---|---|
| Bayer Healthcare Pharmaceuticals Inc. | 10 | $254 |
| AstraZeneca Pharmaceuticals LP | 5 | $231 |
| ABBVIE INC. | 16 | $221 |
| Teva Pharmaceuticals USA, Inc. | 8 | $211 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 10 | $157 |
| Corcept Therapeutics | 6 | $142 |
| Lilly USA, LLC | 8 | $133 |
| Aimmune Therapeutics, Inc. | 4 | $84 |
| Amgen Inc. | 3 | $65 |
| Exact Sciences Corporation | 4 | $59 |
Products named: Kerendia, VRAYLAR, FARXIGA, AUSTEDO XR, CAPLYTA, Korlym, VOWST, MOUNJARO.
Industry payments across TX — which companies pay providers there.
